U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07491497) titled 'A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC' on March 11.
Brief Summary: The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung cancer (NSCLC). The trial will also evaluate the antitumor activity of TRI-611 in adults with ALK-positive NSCLC.
The study will be conducted in two parts. The first part will examine different doses of TRI-611. The second part will look at how well TRI-611 works on ALK-positive NSCLC when administered to three groups of participants that differ based on what type of prior therapy they have recei...